DAWN | Day One Biopharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	13.95 - 14.74
52 Week Range	9.67 - 18.07
Beta	-0.70
Implied Volatility	69.40%
IV Rank	8.95%
Day's Volume	465,757
Average Volume	986,859
Shares Outstanding	87,760,500
Market Cap	1,246,199,100
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-05-27

Valuation
Profitability
Growth
Health
P/E Ratio	-7.32
Forward P/E Ratio	N/A
EPS	-1.94
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	174
Country	USA
Website	DAWN

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

DAWN's peers: ABEO, ABOS, ABSI, ACHV, ACLX, AFMD, AGIO, ALDX, ALLK, ALNY, ALT, ALZN, AMLX, ANNX, ANVS, APLS, APLT, ARCT, ARGX, ARQT, ARWR, ASND, AUTL, AXSM, BBIO, BCLI, BCRX, BCTX, BHVN, BIVI, BMRN, BPMC, BTAI, CABA, CERE, CGEM, CGTX, CLDX, CMRX, CNTX, CPRX, CRBP, CRDF, CRIS, CRVS, CTXR, CUE, XFOR, INZY, MREO, TERN, ELDN, HOOK, PDSB, DMAC, DNLI, DTIL, ETNB, EYPT, FGEN, FOLD, GLSI, GLTO, GMAB, GTHX, GNLX, HRTX, IDYA, IMVT, INKT, INSM, INVA, ITOS, KNSA, KURA, KZIA, LEGN, LPTX, LRMR, LXRX, LYRA, MDGL, MDXG, MDXH, MEIP, MESO, MGNX, MIRM, MIST, MNKD, MRSN, NCNA, NERV, OCUL, OMER, ONCY, OTLK, PGEN, PHAT, PRQR, PRTG, PTGX, QURE, RARE, RCKT, RCUS, RGNX, RIGL, RLAY, RNA, ROIV, RPRX, RVNC, RXRX, SAGE, SANA, SLNO, SLS, SPRB, SWTX, TCRX, TSHA, TSVT, UTHR, VCEL, VIR, VKTX, VOR, VRNA, VYGR, WVE, XBIT, XERS, YMAB, ZNTL, ZYME, MLTX, ERNA, IRON, COYA, GPCR

*Chart delayed

Analyzing fundamentals for DAWN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see DAWN Fundamentals page.

Watching at DAWN technicals we can see that long-term trend is bullish, while middle-term trend is bearish, but short-term trend is bullish. More technicals details can be found on DAWN Technicals page.